Page 4 - Pharma Industry

Sustainable pricing

Govt and vaccine makers should be transparent

Spike in counterfeiting of PPE kits, sanitisers during Covid-19: Report

The COVID-19 lockdown witnessed a sharp spike in counterfeiting incidents in pharmaceutical products, especially PPE kits and sanitisers, as per a report by industry body ASPA. Counterfeiting incidents in India have risen "rapidly in the last few years, with a 20 per cent growth from January 2018 to December 2020, the Authentication Solution Providers' Association (ASPA) said. The top five sectors which have been most affected by counterfeiting are -- alcohol, tobacco, FMCG packaged goods, currency and pharmaceuticals. They together constitute more than 84 per cent of the total counterfeiting incidents reported. Within the last month, there have been a number of cases reported of fake COVID-19 medication. "Counterfeiters are taking advantage of the high demand for medicines, health supplements, safety products, hygiene products and other essentials created due to the COVID crisis and contaminating the market by selling fake and sub-standard products," said the report, titled 'The .

Covid-19 vaccine manufacturers, private hospitals face revenue loss

Back-of-the-envelope calculations show that Serum Institute of India (SII) will lose revenues worth Rs 26.25 crore a month, while Bharat Biotech would lose to the tune of Rs 45 crore a month

After 7,700% surge in stock, Orchid Pharma to face reality check

New owners have to divest part of their stake of about 98 per cent in the firm, which re-listed in Mumbai in early November after emerging from bankruptcy

Powerful lobbying in US against India's Covid vaccine IP waiver push

While big pharma has vehemently opposed India's move on compulsory licensing, even non-pharma influencers such as Bill Gates are against sharing vaccine technology without patenting

Govt gives approval to four firms under PLI scheme for bulk drugs

The government has given approval to four waitlisted firms under the Production Linked Incentive (PLI) scheme for domestic manufacturing of bulk drugs, an official statement said on Monday. The Department of Pharmaceuticals had launched the PLI scheme for promotion of domestic manufacturing of critical bulk drugs -- Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs). It envisages setting up greenfield plants in four different target segments with a total outlay of Rs 6,940 crore for the period 2020-21 to 2029-30. All the 215 applications received for the 36 products spread across the four target segments were considered and appraised and selected participants duly informed, the Ministry of Chemicals and Fertilizers said. Now, four waitlisted applicants who are otherwise eligible have been approved against slots vacated by withdrawal by companies which had earlier been granted approvals, the ministry said. The companies which have been gi

These two bright minds have made Zeno Health a force to reckon with in Pharma industry

Founded by two IIT Bombay alumni, Mumbai based company Zeno Health is changing pharmaceutical industry.

Zydus Cadila Q4 net up 73% to Rs 679 cr, total income up a marginal 3%

During Q4FY21, firm launched Virafin to treat moderate infections in adult Covid-19 patients. Its ZyCoV-D plasmid DNA vaccine is at an advanced stage of Phase-3 trials

GST panel rejects demand for tax waiver on Covid-19 vax, ventilator

GST fitment panel has recommended a short-term rate cut on four Covid-19 related items

PharmEasy acquires Medlife, becomes India's largest e-pharma company

As Medlife discontinues operations, its users will move seamlessly to Pharmeasy, which will now serve 2 million households every month

Biotech cos Tzar Labs and Epigeneres to launch early-detection cancer tests

Firms claim breakthrough with their RNA-marker tech which detects cancer even in stage zero

Pharma sector's Q4 results show moderate gains amid Covid-19 pandemic

The ongoing April-June quarter should see strong growth due to low base of last year

Cipla open to forge a partnership to distribute Covid-19 vaccines in India

The company already makes and markets antiviral drugs like remdesivir, favipiravir in India apart from importing and distributing Roche's tocilizumab (Actemra)

Alembic Pharma Q4 net up 12% to Rs 251 cr on strong API, global businesses

Net sales rise 6% to Rs 1,280 cr; API business expands by as much as 38%

State govts begin vaccine price negotiations, eye Rs 150 per dose

States would have to fund procurement from their own budgets and bridge funding from the Centre is unlikely

Pharma poised for an excellent FY22 on the back of Covid-led demand

Improving exports and a weak rupee could support profit boost

Strong injectables portfolio to support Aurobindo Pharma's growth

The stock has been underperforming recent months and trades at a discount to peers

Shortage of key chemical hits Bharat Biotech's Covaxin ramp-up plans

Bharat Biotech is trying to ramp up capacities of Covaxin to 12 million doses per month by July, from the current 5 million doses per month

Alembic Pharma's injectables plant launch may face some delay

Company saw Form 483 with observations issued by US FDA for injectables plant in February

Piramal Pharma to acquire 100% stake in Hemmo Pharma for Rs 775 cr

Consequent to the acquisition, Hemmo Pharmaceuticals Pvt Ltd would become a wholly-owned subsidiary of Piramal Pharma Ltd